A New Podcast from Obstetrics & Gynecology, featuring members from the Editorial Team and contributing authors, each month as they highlight the latest research and practice updates in the field. This episode features an interview with Drs. Catherine T. Witkop and Amy G. Cantor, authors of “Recommendations From the Women’s Preventive Services Initiative on Breast Cancer Screening for Women at Average Risk and Patient Navigation Services for Breast and Cervical Cancer Screening.”

#265: Stephen Quandt at https://catbehaviorhelp.com/ really likes lickable treats for cats — and Catit's new Creamy really rings their bell! The cats for adoption at the NYC Animal Care & Control [where Stephen works with them to help make them more adoptable] have shown more response to Creamy than any other treat Stephen has tried with them!

Matt & Gaby are on assignment this week, so we present an encore presentation of one of our most popular episodes. This one is super fun and comes from Sept. 16, 2024. We hope you enjoy it.--- What if humans were the latest must-have pet for trendy aliens? This episode explores the hilarious and bizarre scenario of extraterrestrial beings snatching us up like puppies from a shelter. From alien vets poking and prodding us for space parasites to the culinary delights of human kibble, we dive into

Interfaith Cooperation for Peace: Why It Matters Now More Than Ever

Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate

Host: Brian P. McDonough, MD, FAAFP Guest: Mylynda Massart, MD, PhD Given its ability to identify universal cancer signals across multiple tumor types, multi-cancer early detection (MCED) testing is emerging as a promising tool to complement traditional, single-cancer screening methods. Joining Dr. Brian McDonough to share practical strategies for introducing MCED testing into clinical workflows and enhancing patient engagement is Dr. Mylynda Massart. Not only is she an Associate

Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.

هل التوثيق الطبي مجرد ورق زائد يضيع وقت الطبيب؟ أم هو المفتاح الخفي لإنقاذ الأرواح وتحسين جودة الرعاية؟ في هذه الحلقة من ليبيا مِدكاست، يناقش د. أحمد الدور الجوهري للتوثيق الطبي، ويكسر التصور الشائع بأنه عبء إداري بلا قيمة. من خلال أمثلة واقعية من ليبيا وأدلة عالمية، يوضح كيف أن التوثيق الطبي ليس مجرد كتابة … Continue reading Episode 7: Medical Documentation: The Hidden Key to Clinical Reasoning and Better Care. التوثيق الطبي: المفتاح الخفي للتفكير السريري وجودة الرعاية

Many QIAGEN Ingenuity Pathway Analysis (IPA) users have expressed strong interest in taking advantage of public single-cell expression data. Such data is readily available and easily accessible in IPA. We are hosting a 1hr training focused on some common use cases related to this topic.You'll learn to:• Easily locate single-cell studies, samples or cell types of interest• Study pathways and networks pertaining to such projects to explore biological and cellular mechanisms• Investigate sample- and

In this 90-minute video, users will learn how to discover and validate biomarkers, key regulators and targets through harnessing uniformly-processed public data from sources such as GEO, SRA, cancer collections (TCGA, CCLE etc.), normal tissue/cell type collections (GTEx, HPA etc.) and more using QIAGEN Omicsoft Lands.

Single-cell gene expression analysis helps biologists and bioinformaticians reveal complex and rare cell populations, uncover regulatory relationships among genes and analyze and visualize gene expression differences among different cell types, or within a unique cell type. In this talk we will explore new tools for analyzing, interpreting and explore scRNA-seq data and the underlying biology. We will also show how to integrate ‘omics datasets from different platforms to gain insights into the

QIAGEN OmicSoft Lands and QIAGEN Ingenuity Pathway Analysis (IPA) provide a powerful resource for exploring curated pre-analyzed public single-cell RNA-seq studies and providing downstream biological insights for these data. In this training, we will review how OmicSoft Lands allows for the interrogation of identified cell types within public single-cell datasets of interest and subsequent exploration of their associated gene signatures. The biological context of these signatures can then be

In this training, users will learn how to generate downstream outputs such as heatmaps, differential expression tables, PCA/PCOA plots, box plots and other visualizations from their count or expression data (transcriptomics, proteomics, metabolomics, etc.). Attendees will learn how to: • Import either normalized or raw count data (transcriptomics, proteomics, metabolomics, etc.) into QIAGEN OmicSoft Studio • Generate downstream outputs such as differential expression tables, heatmaps, counts,

In this 90-minute training, users will learn how to do drug treatment, toxicology and target safety assessment related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands. Using public data from GTEx (normal tissue), GEO, cancer collections and more, attendees will learn how to use Omicsoft Lands to: • Investigate a drug target or biomarker expression across different normal tissues, disease conditions, treatments and more • Correlate expression of 2 or more genes •

In this 90-minute training, attendees will learn how to use basic expression analysis functionalities in QIAGEN OmicSoft OncoLand. QIAGEN OmicSoft Single Cell Land will also be discussed, focusing on public single-cell data. Key focus will be on Biomarker discovery with QIAGEN OmicSoft OncoLand leveraging public oncology data from GEO, TCGA and other collections to: • Discover and validate biomarker expression in diseases, disease subtypes, treatments, cell types, etc. • Identify a list of

This training will focus on how QIAGEN Omicsoft Studio and IPA can be used to discover new biomarkers, validate (or study) drug targets and identify novel mechanisms of action with user and/or public checkpoint inhibitor datasets from resources like GEO, SRA, TCGA and more.In this training, you will learn how to:· Investigate the expression of a gene/biomarker/drug target across different treatments and diseases· Derive a biomarker/gene signature from a specific condition (for example,

Slides from this training:https://qiagen.showpad.com/share/qm9IZA718x6x5h6pfsiTa Single cell lands tutorials: https://omicsoftdocs.github.io/ArraySuiteDoc/tutorials/SingleCellLand/Gene_Views/ Single cell RNA-sequencing (scRNA-seq) has been widely used to investigate tissue heterogeneity, identify novel cell types, study pathogenic mechanisms, development of targeted therapy (including immunotherapy) and more. Accordingly tremendous amount of scRNA-seq data has been deposited to public domains like

Single cell RNA-sequencing (scRNA-seq) has been widely used to investigate tissue heterogeneity, identify novel cell types, study pathogenic mechanisms, development of targeted therapy (including immunotherapy) and more. Accordingly tremendous amount of scRNA-seq data has been deposited to public domains like GEO. In this training, attendees will learn how to · Locate public single cell studies of their interest using Omicsoft Single Cell Lands · Study different cell types by dimension reduction

Have you ever tried to access the genomic profiles of cell lines before using them in your preclinical experiments just to come up empty-handed? Maybe you’ve scoured public databases for gene expression information on your cell line to find the reported genomic profile doesn't match the cell line data you recently purchased? We understand that knowing the genomic identity of your cell lines is fundamental to the success of your preclinical experiments. Unfortunately, most publicly available sources